Zelluna Immunotherapy

Developing allogeneic TCR-NK therapies for solid tumors

Add To Watchlist
General Information
Company Name
Zelluna Immunotherapy
Founded Year
2016
Location (Offices)
Norway
Founders / Decision Makers
Namir Hassan - Chief Executive Officer Hans Ivar Robinson - Chairman & Co-Founder Bent Jakobsen - Board Member & Advisor Anders Holm - COO & Head of business development
Number of Employees
25
Industries
Biotechnology, Health Care, Pharmaceutical
Funding Stage
Series Unknown
Social Media

Zelluna Immunotherapy - Company Profile

Zelluna is a Norway-based biotechnology company founded in 2016. The company is focused on pioneering allogeneic T cell receptor (TCR) guided natural killer (NK) cell immunotherapies for the treatment of solid cancers. Zelluna's slogan "Developing allogeneic TCR-NK therapies for solid tumors" encapsulates its mission. The company is dedicated to developing a portfolio of tumor-specific TCRs aimed at guiding NK cells to induce safe, efficient, and durable cancer responses. Zelluna recently received a Venture Round investment on 25 August 2022 from Takeda Pharma. For more information, please visit www.zelluna.com.

Taxonomy: Immunotherapy, Cancer treatment, Adoptive cell therapy, T cell receptor technologies, Solid tumors, Biopharmaceutical, Cellular therapy, Allogeneic TCR-NK therapies, GMP facilities, Oslo Cancer Cluster, Norwegian Radium Hospital, Research and development, Immunooncology, Norwegian biotechnology

Funding Rounds & Investors of Zelluna Immunotherapy (4)

View All
Funding Stage Amount No. Investors Investors Date
Venture Round Unknown 1
Takeda Pharma, investor in Zelluna Immunotherapy's Venture Round round
25 Aug 2022
Grant Unknown - 11 Jun 2020
Venture Round €7.50M - 11 Jun 2020
Seed Round Unknown 1
Birk Venture, investor in Zelluna Immunotherapy's Seed Round round
01 Jan 2017

Latest News of Zelluna Immunotherapy

View All

No recent news or press coverage available for Zelluna Immunotherapy.

Similar Companies to Zelluna Immunotherapy

View All
T Cell Nouveau - Similar company to Zelluna Immunotherapy
T Cell Nouveau Clinical stage biopharmaceutical company with novel TCR like CAR-T cell therapy for solid tumors at affordable price
TC BioPharm - Similar company to Zelluna Immunotherapy
TC BioPharm Treating cancer with γδ T cells | Nasdaq Ticker - $TCBP
Caribou Biosciences - Similar company to Zelluna Immunotherapy
Caribou Biosciences Clinical-stage biopharmaceutical company developing transformative therapies to treat devastating human diseases
Matterhorn Biosciences - Similar company to Zelluna Immunotherapy
Matterhorn Biosciences M-TCR cell therapies targeting a new hallmark of cancer
CytoArm｜BsAb Armed-T Therapy Platform Revolutionizing T Cell Cancer Treatment - Similar company to Zelluna Immunotherapy
CytoArm｜BsAb Armed-T Therapy Platform Revolutionizing T Cell Cancer Treatment Innovative BsAb Armed-T therapy platform utilizes non-viral bi-functional antibodies (BsAb) to empower T cells.
Circle Decoration Circle Decoration

Want to dive deeper into Zelluna Immunotherapy? Join now to access exclusive insights and find similar companies like this — powered by AI analytics.

Register Now